B-Cell Lymphoma Immunotherapy Using TLR9-targeted Oligonucleotide STAT3 Inhibitors

Molecular Therapy - United States
doi 10.1016/j.ymthe.2018.01.007
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Cell-Selective Oligonucleotide STAT3 Inhibitor for Immunotherapy of Human Acute Myeloid Leukemia

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2015English

Inhibition of the STAT3 Target SGK1 Sensitizes Diffuse Large B Cell Lymphoma Cells to AKT Inhibitors

Blood Cancer Journal
OncologyHematology
2019English

Beta-Adrenergic Signaling Impairs Anti-Tumor CD8+ T Cell Responses to B Cell Lymphoma Immunotherapy

Cancer immunology research
Cancer ResearchImmunology
2017English

TLR9 Agonists Induced Cell Death in Burkitt's Lymphoma Cells Is Variable and Influenced by TLR9 Polymorphism

Cell Death and Disease
Molecular NeuroscienceImmunologyCell BiologyCancer ResearchCellularMedicine
2012English

Integration of HIV-1 Caused STAT3-associated B Cell Lymphoma in an AIDS Patient

Microbes and Infection
Infectious DiseasesImmunologyMicrobiology
2007English

Antibody-Targeted Paclitaxel Loaded Nanoparticles for the Treatment of CD20+ B-Cell Lymphoma

Scientific Reports
Multidisciplinary
2017English

Regulatory B Cell Production of IL-10 Inhibits Lymphoma Depletion During CD20 Immunotherapy in Mice

Journal of Clinical Investigation
Medicine
2011English

B Cell-Intrinsic TLR9 Expression Is Protective in Murine Lupus

Journal of Clinical Investigation
Medicine
2020English

Inhibition of Β-Catenin/B Cell Lymphoma 9 Protein−protein Interaction Using Α-Helix–mimicking Sulfono-Γ-AApeptide Inhibitors

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy